ESG Report 2020

The direction of the Group s research and qualification exceeds 30%. At the same time, it is development includes new drugs and high-value equipped with more than 100 large-scale research generic drugs. Key research and development and development equipment with leading areas involve endocrine medications, autoimmune technologies in the Country and abroad. The disease medications, ophthalmic medications, investment in assets exceeds RMB160 million, veterinary medicines, etc. During the Year, the which is conducive to the research and Group s independently-developed rheumatoid development of the Group. The Department of arthritis drug was approved for clinical trials by Clinical Medicine is responsible for the design, the National Medical Products Administration. At organisation, implementation, quality management the same time, the two new types of veterinary and compliance and related work of all clinical trial medicines have obtained the certificate in new projects. It also closely cooperates with more than veterinary drug issued by the Ministry of 100 domestic institutions with national drug Agriculture and Rural Affairs, and was approved clinical trial qualifications and authoritative for listing. treatment in related fields. Under the guidance of well-known experts in the Country and abroad, we The Group has established the Chemical Research have organised and completed more than 70 Institute, the Biological Research Institute and the clinical trials of pharmaceuticals. At the same Department of Clinical Medicine to cooperate in time, the Group's Department of Research and research and development. The research institutes Development also cooperates with universities to are equipped with research talents and advanced carry out research and development work to equipment. Taking the Biological Research Institute achieve better research and development results. as an example, there are nearly 150 research and development personnel, and the proportion of personnel with graduate or above academic ’ ’ Research and Development Investment and Achievements The Group adheres to innovative research and development, continues to invest a lot of resources, and gradually increases investment in research and development. Investment in research and development during the Year was RMB340 million, and it accounted for 9.1% of the sales revenue of the finished products business. RESEARCH , DEVELOPMENT AND INNOVATION Investment in R&D 340 368 283 2018 2019 2020 (RMB million) 51 Environmental, Social and Governance Report 2020 The United Laboratories International Holdings Limited